Full steam ahead at F2G
The UK developer has the launch of what could be the first in a new class of antifungals in its sights.
Glaxo gets a Shingrix boost
But pressure is on the shingles vaccine as the consumer spin-off approaches.
Biotech catalysts on the horizon
The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.
Biohaven’s high-risk bet
There are long shots and then there is troriluzole. Biohaven will soon find out if it was wise to press on with the asset.
Global pharma stocks struggle in the third quarter
A strong performance from a handful of large drug developers could not rescue the sector from a weak three months on the stock market.
Biotech’s key fourth-quarter data
Deciphera, Allakos and Uniqure are all set for important data disclosures.
